Stockwatch: The end of the affair with gene therapy
This article was originally published in Scrip
The End of the Affair, a 1951 novel by Graham Greene, depicts some of the worst human emotions that can accompany the ending of a relationship, and then after a break of two years, the re-ignition of those emotions in an investigative post-mortem. Way back at the start of this century I invested in a gene therapy company. Although the inevitable end of the affair caused me some heartache, unlike the principal characters in Mr Greene's classic novel I found it a valuable cathartic learning experience to have lost some money in this unproven area of biotechnology.
You may also be interested in...
A complete response letter from the FDA in June knocked Intercept’s stock price down to 2014 levels, but perhaps the regulator is sending wider messages about NASH.
A complete response letter from the FDA knocked Intercept’s stock price for six, but perhaps the FDA is sending wider messages about NASH.
Gene and cellular therapies that can replace decades of expensive therapy do not come cheap. Even the initial remedy of payment by installments could be irrelevant when not all patients respond in the same way.